Pramlintide
Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects
AstraZeneca · Phase 2 · Completed · Enrollment 636
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Placebo-P + Placebo-M | Obesity or overweight | n/r | n/r | n/r | n/r |
| Pramlintide 360 mcg + Placebo-M | Obesity or overweight | 360 mcg | n/r | n/r | n/r |
| Placebo-P + Metreleptin 5.0 mg | Obesity or overweight | 5.0 mg | n/r | n/r | n/r |
| Pramlintide 180 mcg + Metreleptin 2.5 mg | Obesity or overweight | 2.5 mg | n/r | n/r | n/r |
| Pramlintide 180 mcg + Metreleptin 5.0 mg | Obesity or overweight | 5.0 mg | n/r | n/r | n/r |
| Pramlintide 360 mcg + Metreleptin 1.25 mg | Obesity or overweight | 1.25 mg | n/r | n/r | n/r |
| Pramlintide 360 mcg + Metreleptin 2.5 mg | Obesity or overweight | 2.5 mg | n/r | n/r | n/r |
| Pramlintide 360 mcg + Metreleptin 5.0 mg | Obesity or overweight | 5.0 mg | n/r | n/r | n/r |